Screening Compounds for TWEAK-Fn14 Interaction Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting the TWEAK-Fn14 pathway lack effective small molecule tools, hindering the therapeutic potential of inhibiting key nodes of this signaling pathway, which is crucial for various disease states including cancer and autoimmune disorders.
Innovation Solution
Development of screening methods involving protein-protein docking models, NMR structures, and pharmacophoric site matching to identify compounds that modulate the TWEAK-Fn14 interaction, followed by iterative screening of a targeted library to enrich for active compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current methods are used for targeting the TWEAK-Fn14 pathway, then the existing therapeutic approaches can be maintained, but the therapeutic potential of inhibiting key nodes of this signaling pathway cannot be realized due to lack of effective small molecule tools
Solution Approach 1:
The patent uses NMR structures and protein-protein docking models to create computational copies and models of the TWEAK-Fn14 interaction, enabling virtual screening of compound libraries without requiring physical interaction assays for every compound. This copying approach allows identification of small molecule inhibitors that can modulate the TWEAK-Fn14 pathway.
Solution Approach 2:
The patent introduces pharmacophoric site matching as an intermediary step between protein structure and compound screening. By identifying key pharmacophoric sites on the Fn14 receptor that interact with TWEAK, the patent creates a mediator model that guides the selection of small molecule compounds capable of blocking this interaction, thus enabling therapeutic intervention.
2Measurement precision
If protein-protein docking models and NMR structures are used for screening, then compounds targeting the TWEAK-Fn14 interaction can be identified, but the complexity of the screening process increases
Solution Approach 1:
The patent performs preliminary actions by generating NMR structures and protein-protein docking models before the actual compound screening process. These pre-computed structural models and identified pharmacophoric sites serve as ready-to-use tools that guide subsequent compound evaluation, reducing the need for complex real-time analysis during screening.
Solution Approach 2:
The patent segments the Fn14 receptor structure into distinct pharmacophoric sites that are critical for TWEAK binding. By dividing the binding interface into discrete functional regions, the patent simplifies the screening process by allowing compounds to be evaluated based on their ability to interact with specific pharmacophoric features rather than requiring comprehensive analysis of the entire protein surface.
Data Source
AI summary
The present disclosure is directed to methods of screening a compound for modulating activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of fibroblast growth factor-inducible 14 (Fn14). The present disclosure also provides heterocyclic compounds and pharmaceutically acceptable salts thereof and methods for the prevention, treatment, and amelioration of cell proliferative disorders with these compounds.